Who Owns Fate Therapeutics Inc (FATE)? 13F Institutional Holders (Q2 2026)

FATE ranks #3584 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

157 institutions disclose a position in FATE, but none treat it as a major bet — even Redmile Group, LLC, its most concentrated holder, allocates just 2.3% of its own portfolio to it.

Assenagon Asset Management S.A. has added to its FATE position for two straight quarters, increasing it by $2.9M to reach $3.1M today.

FATE is down 7.3% today, but institutions show net buying of $7.3M this quarter — a divergence between today's price move and the underlying institutional flow.

FATE reported a net loss of $126.0M over the trailing twelve months.

• Not yet profitable — net loss of $126.0M over the trailing twelve months
• Revenue declined 23.4% year over year
• Net income improved year over year, from -$171.5M to -$126.0M
• Operating cash flow was negative, using $106.1M in cash
• Current ratio of 5.79x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting